AVIR
NASDAQAtea Pharmaceuticals Inc.
News · 26 weeks33+100%
2026-03-012026-08-23
Mix1790d
- Insider8(47%)
- Other4(24%)
- SEC Filings3(18%)
- Earnings2(12%)
Latest news
25 items- SECSEC Form 10-Q filed by Atea Pharmaceuticals Inc.10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- SECAtea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- PRAtea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdatePhase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027 AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV) Company Holding Conference Call Today at 4:30 pm ET BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported
- PRAtea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2026, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals web
- PRAtea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C VirusBemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa®), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in a Global Phase 3 Program of Hepatitis C Virus (HCV) Treatments Results Reinforce Potential Best-in-Class Profile of BEM/RZR as a Short 8-Week Treatment for Patients Without Cirrhosis Up to 4 Million People in the US Living with HCV, Which Can Progress to Cirrhosis, End-Stage Liver Disease and Liver Cancer if Left Untreated BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company dev
- PRAtea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E VirusPhase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No Approved Therapies Study Initiation Represents an Important Milestone Advancing Atea’s Antiviral Pipeline Focusing on First- or Best-in-Class Product Candidates in Areas of High Unmet Medical Need BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the initiation of
- PRAtea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusTopline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for the Treatment of HCV BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced completion of patient enrollment in C-FORWARD, its Phase 3 clinical trial outside North America, evaluating the regimen of bemnifosbuvi
- INSIDERDirector Lucidi Bruno converted options into 29,600 shares, increasing direct ownership by 26% to 142,350 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERSEC Form 4 filed by Director Berman Howard4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERDirector Berger Franklin M converted options into 29,600 shares, increasing direct ownership by 6% to 536,097 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERDirector Adams Jerome M. converted options into 29,600 shares, increasing direct ownership by 47% to 92,350 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERSEC Form 4 filed by Director Kirsch Arthur S4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERDirector Murphy Polly A. converted options into 29,600 shares, increasing direct ownership by 32% to 121,745 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERDirector Polsky Bruce converted options into 29,600 shares, increasing direct ownership by 31% to 124,806 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERDirector Duncan Barbara Gayle converted options into 29,600 shares, increasing direct ownership by 47% to 92,350 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SECSEC Form 8-K filed by Atea Pharmaceuticals Inc.8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- PRAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating h
- INSIDERAmendment: Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERDirector Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- PRAtea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis PipelineBOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain. The presentations include two posters supporting Atea's fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented and d
- SECSEC Form 10-Q filed by Atea Pharmaceuticals Inc.10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- SECAtea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- PRAtea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateC-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026 Encouraging Preclinical Data Support AT-587 as a Potential First-in-Class Therapy for Hepatitis E Virus (HEV); Phase 1 Initiation Expected Mid-2026 Company Holding Conference Call Today at 4:30 pm ET BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of ora
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
- PRAtea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2026, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website a
AVIR FAQ
7 questionsWhat does Atea Pharmaceuticals Inc. do?
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in...Where does AVIR stock trade?
Atea Pharmaceuticals Inc. (AVIR) is listed on NASDAQ.What sector and industry is AVIR in?
Atea Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Atea Pharmaceuticals Inc. go public?
Atea Pharmaceuticals Inc. (AVIR) completed its IPO in 2020.What are analysts saying about AVIR?
Atea Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $688.00 price target on 2024-08-13. Recent price targets range from $688.00 to $1100.00.What companies are similar to AVIR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AVIR side-by-side with any of them on Quantisnow.How can I track AVIR on Quantisnow?
Quantisnow aggregates Atea Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVIR to receive live email and push alerts on every new disclosure.